AAA
DRNA

Affinity Asset Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Affinity Asset Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40,000
Closed -$881K – 89
2020
Q4 		$881K Buy
+40,000
New +$881K 0.47% 44

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Affinity Asset Advisors's DRNA Position: Q1 2021 in Review

Affinity Asset Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2021, closing a stake of 40,000 shares — an estimated $881K sold.

Affinity Asset Advisors first reported a position in DRNA in Q4 2020 and held it in 1 quarter. The position peaked at $881K in Q4 2020. 183 funds tracked by Wall St. Rank hold DRNA as of Q1 2021.

  • Affinity Asset Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 40,000 Dicerna Pharmaceuticals, Inc. shares in Q1 2021, an estimated $881K.
  • Affinity Asset Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Affinity Asset Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $881K in Q4 2020.
  • 183 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2021.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.